Get the Stockscreener App
2.27
2.75%
-0.06
Maxcyte Inc stock is traded at $2.27, with a volume of 172.01K.
It is down -2.75% in the last 24 hours and up +2.30% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.33
Open:
$2.29
24h Volume:
172.01K
Relative Volume:
0.20
Market Cap:
$241.03M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-6.6765
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+5.40%
1M Performance:
+2.30%
6M Performance:
-51.37%
1Y Performance:
-48.73%
1-Day Range:
$2.24
$2.33
1-Week Range:
$2.02
$2.37
52-Week Range:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.265 | 238.15M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
125.09 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.56 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
397.70 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.03 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.58 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Published on: 2025-07-23 21:52:41 - Autocar Professional
What drives MaxCyte Inc. stock priceFree Technical Analysis Support - Autocar Professional
What analysts say about MaxCyte Inc. stockFree Real-Time Stock Data - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastHigh-yield capital appreciation - jammulinksnews.com
Is MaxCyte Inc. a good long term investmentPhenomenal capital appreciation - Autocar Professional
Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
How MaxCyte Inc. stock performs during market volatilityDaily Swing Candidates - Newser
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia
PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama
Business Wire - JIJI PRESS
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks
MaxCyte shares trading for last time in London - Sharecast.com
Moving Gene Editing Advances Into the Clinic - the-scientist.com
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX
MaxCyte shareholders approve equity plan expansion, AIM delisting By Investing.com - Investing.com UK
California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa
MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma
Market news - investments.halifax.co.uk
MaxCyte enters collaboration with Ori Biotech - Sharecast.com
MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soleymannezhad Ali | Chief Commercial Officer |
Mar 18 '25 |
Sale |
3.18 |
1,211 |
3,850 |
59,439 |
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.09%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):